<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287937</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02676</org_study_id>
    <secondary_id>PHI 51</secondary_id>
    <secondary_id>U01CA099168</secondary_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>CDR0000454713</secondary_id>
    <nct_id>NCT00287937</nct_id>
  </id_info>
  <brief_title>Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors</brief_title>
  <official_title>Phase I Study Of Suberoylanilide Hydroxamic Acid (SAHA) (NSC 701852) in Combination With Paclitaxel /Carboplatin for Advanced and Refractory Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of vorinostat when given&#xD;
      together with paclitaxel and carboplatin in treating patients with advanced or refractory&#xD;
      solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving vorinostat together with paclitaxel and carboplatin may&#xD;
      kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the recommended phase II dose of vorinostat (SAHA) when administered with&#xD;
      paclitaxel and carboplatin in patients with advanced or refractory solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the dose-limiting toxicity (DLT) and other toxic effects of this regimen in&#xD;
      these patients.&#xD;
&#xD;
      II. Assess, preliminarily, evidence of antitumor activity of this regimen in these patients.&#xD;
&#xD;
      III. Determine the pharmacokinetic parameters of this regimen in these patients.&#xD;
&#xD;
      IV. Determine the in vivo effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of vorinostat (SAHA).&#xD;
&#xD;
      Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours&#xD;
      followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up&#xD;
      to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who&#xD;
      have stable disease after the completion of 6 courses may receive single-agent SAHA at the&#xD;
      discretion of the treating physician.&#xD;
&#xD;
      NOTE: *During the first treatment course only, patients receive SAHA on days -4 to 10.Cohorts&#xD;
      of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is&#xD;
      determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients&#xD;
      experience DLT. An additional 6-12 patients are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD of vorinostat defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity graded using the CTC version 2.0</measure>
    <time_frame>Up to 1 month after completion of study treatment</time_frame>
    <description>Tables will be created to summarize these toxicities by dose and by course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 month after completion of study treatment</time_frame>
    <description>Summarized with Kaplan-Meier plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to failure</measure>
    <time_frame>Up to 1 month after completion of study treatment</time_frame>
    <description>Summarized with Kaplan-Meier plots.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response defined using the RECIST criteria</measure>
    <time_frame>Up to 1 month after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat, paclitaxel, carboplatin)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
          -  No untreated brain metastases&#xD;
&#xD;
               -  Patients with stable brain disease (no concurrent corticosteroids) ≥ 4 weeks&#xD;
                  after completion of appropriate therapy are eligible&#xD;
&#xD;
          -  ECOG performance status ≤ 2 OR Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double barrier contraception for at least 1 week&#xD;
             before, during, and for at least 2 weeks after study participation&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No history of allergic reactions to paclitaxel&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to study drugs&#xD;
&#xD;
          -  No inability to take oral medications on a continuous basis&#xD;
&#xD;
          -  No psychiatric illness or social situation that would limit compliance with this study&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for advanced/metastatic disease&#xD;
&#xD;
               -  Adjuvant chemotherapy administered ≥ 2 years prior to study entry is not&#xD;
                  considered a prior chemotherapy regimen for purposes of this study&#xD;
&#xD;
          -  No prior therapy with paclitaxel&#xD;
&#xD;
          -  No chemotherapy or radiotherapy within the past 3 weeks (6 weeks for nitrosoureas or&#xD;
             mitomycin C) and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior valproic acid&#xD;
&#xD;
          -  No other concurrent anticancer therapies or agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent oral contraceptives&#xD;
&#xD;
          -  No concurrent prophylactic growth factors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suresh Ramalingam</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

